The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | MSI in patients with stage III colon cancer receiving 5-FU with or without oxaliplatin

Name: MSI in patients with stage III colon cancer receiving 5-FU with or without oxaliplatin
Uploaded: 2021-01-15T00:00:00Z
Duration: 2 min 32 s
Description: Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, outlines the results of a meta-analysis of 12 adjuvant trials evaluating the efficacy of adjuvant fluoropyrimidine with or without oxaliplatin in patients with microsatellite instable (MSI) stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Romain Cohen • 15 Jan 2021

ASCO GI 2021

Colon Cancer Gastrointestinal Cancer 5-fluorouracil Oxaliplatin

Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, outlines the results of a meta-analysis of 12 adjuvant trials evaluating the efficacy of adjuvant fluoropyrimidine with or without oxaliplatin in patients with microsatellite instable (MSI) stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).